Penny stocks are generally very low-priced shares that can offer explosive upside if the underlying business becomes successful. However, they also come with higher risks than established companies. One such company is Werewolf Therapeutics (HOWL), a clinical-stage biotechnology firm that is developing therapies designed to activate the immune system against cancer and other immune-mediated disorders.
HOWL stock has surged 50% year-to-date (YTD), and has climbed more than 133% over the last five days. A proposed merger with Ambros Therapeutics, as well as a $150 million private placement, may have given the stock a chance to howl its way to the top.
